
Opinion|Videos|January 7, 2025
Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL
Panelists discuss how real-world treatment patterns with covalent BTK inhibitors differ from clinical trial experiences, particularly regarding the rates of discontinuation due to intolerance vs progression and the incidence of cardiac adverse events with acalabrutinib and zanubrutinib in clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What percentage of your patients switch from first-line cBTKi due to intolerance vs progression vs being refractory? How often are you observing cardiac treatment–related AEs with acala and zanu in the real-life day-to-day practice vs what has been reported in the clinical trials?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5



































